Company Description
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.
The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.
The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Quang Pham |
Contact Details
Address: 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 United States | |
| Phone | 904 300 0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1937993 |
| CUSIP Number | 127636207 |
| ISIN Number | US1276362076 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman and Chief Executive Officer |
| John P. Sharp CPA | Interim Chief Financial Officer and Principal Accounting Officer |
| Jeffrey Cole | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 23, 2026 | PRE 14A | Other preliminary proxy statements |
| Jul 21, 2026 | 8-K | Current Report |
| Jul 20, 2026 | EFFECT | Notice of Effectiveness |
| Jul 20, 2026 | 424B3 | Prospectus |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 15, 2026 | D | Notice of Exempt Offering of Securities |
| Jul 13, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 10, 2026 | 8-K | Current Report |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 29, 2026 | 8-K | Current Report |